CHMP gives thumbs up to Sanofi's Intanza flu vacc

Sanofi Pasteur, the vaccines division of French drug major Sanofi-Aventis, says that its seasonal influenza vaccine Intanza/IDflu  has received a positive opinion from the Committee for Medicinal  Products for Human Use (CHMP) of the European Medicines Agency (EMEA).

The CHMP recommended approval of a marketing authorization in the  European Union for the use of product, which is the first intradermal  microinjection flu vaccine.

According to the Paris-based firm, the decision represents a first key  step towards recognition of the ID route as a promising option for  vaccine administration.